U.S. markets closed
  • S&P 500

    4,280.15
    +72.88 (+1.73%)
     
  • Dow 30

    33,761.05
    +424.38 (+1.27%)
     
  • Nasdaq

    13,047.19
    +267.27 (+2.09%)
     
  • Russell 2000

    2,016.62
    +41.36 (+2.09%)
     
  • Crude Oil

    91.88
    -2.46 (-2.61%)
     
  • Gold

    1,818.90
    +11.70 (+0.65%)
     
  • Silver

    20.83
    +0.49 (+2.39%)
     
  • EUR/USD

    1.0257
    -0.0068 (-0.66%)
     
  • 10-Yr Bond

    2.8490
    -0.0390 (-1.35%)
     
  • GBP/USD

    1.2139
    -0.0064 (-0.52%)
     
  • USD/JPY

    133.4800
    +0.4810 (+0.36%)
     
  • BTC-USD

    24,104.33
    -70.45 (-0.29%)
     
  • CMC Crypto 200

    574.64
    +3.36 (+0.59%)
     
  • FTSE 100

    7,500.89
    +34.98 (+0.47%)
     
  • Nikkei 225

    28,546.98
    +727.65 (+2.62%)
     

HOOKIPA Pharma: Q4 Earnings Insights

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

 

Shares of HOOKIPA Pharma (NASDAQ:HOOK) remained unaffected after the company reported Q4 results.

Quarterly Results

Earnings per share decreased 15.00% over the past year to ($0.46), which beat the estimate of ($0.58).

Revenue of $5,163,000 higher by 42.70% from the same period last year, which beat the estimate of $4,260,000.

Outlook

HOOKIPA Pharma hasn't issued any earnings guidance for the time being.

HOOKIPA Pharma hasn't issued any revenue guidance for the time being.

Details Of The Call

Date: Mar 18, 2021

View more earnings on HOOK

Time: 08:30 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/ah8vsuip

Technicals

Company's 52-week high was at $13.68

Company's 52-week low was at $6.00

Price action over last quarter: Up 13.55%

Company Description

HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of antigen-specific killer T cells and antibodies.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.